Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Stephens Inc. AR

Stephens Inc. AR boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 31.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 158,881 shares of the company’s stock after acquiring an additional 37,585 shares during the period. Stephens Inc. AR’s holdings in Novo Nordisk A/S were worth $18,918,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. acquired a new position in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC lifted its stake in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S during the second quarter worth $25,000. Orion Capital Management LLC acquired a new position in Novo Nordisk A/S during the first quarter worth $26,000. Finally, Halpern Financial Inc. lifted its stake in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $111.96 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The firm has a market capitalization of $502.42 billion, a PE ratio of 38.34, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The business’s fifty day moving average price is $124.75 and its 200 day moving average price is $130.93.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The company had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is presently 24.66%.

Analyst Ratings Changes

A number of research analysts have commented on NVO shares. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.